2D QSAR of arylpiperazines as 5-HT1A receptor agonists

Indian Journal of Pharmaceutical Sciences

Volumn 69, Issue 6, 2007, Pages 800-804

  Joshi, Urmila ^a   Tikhele, Sonali ^a   Shah, F ^a  

^a PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

Author keywords

5 HT1A receptor; Agonists; Arylpiperazines; QSAR

Indexed keywords

PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ARTICLE; DRUG STRUCTURE; LIGAND BINDING; LIPOPHILICITY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 40749105808     PISSN: 0250474X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0250-474X.39437     Document Type: Article

References (18)

1. Glennon R. Central serotonin receptors as targets for drug research. J Med Chem 1987;30:1-12.
2. 7. J Med Chem 2003;46:2795-812.
3. Arvidsson LE, Johansson AM, Hacksell U, Nilsson LG, Svensson K, Hjorth S, et al. (+)-cis-8-hydroxy-1-methyl-2-(di-n-propylamino) tetralin: A Potent and Highly Stereoselective 5-Hydroxytryptamine Receptor Agonist. J Med Chem 1987; 30:2105-9.
4. Sanders-Bush E, Mayer S. 5-Hydroxytryptamine (Serotonin): Receptor agonists and antagonists. In; Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman.s The Pharmacological basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 269.
5. Peroutka S. In; Serotonin receptor subtypes. Basic and clinical aspects. New York: Wiley-Liss; 1991. p. 1.
6. 1A receptors. Curr Med Chem 2002;9:443-69.
7. 1A receptor agonists and definition of a steric model of this site. Eur J Med Chem 1989;24:31-7.
8. 1A receptor agonists based on stereoselective methyl- substituted and conformationally restricted analogues of 8-hydroxy-2-(di-n-propylamino) tetralin. J Med Chem 1991;34:497-510.
9. 1A and Dopamine Pharmacophores: X-ray crystal structure and affinities of conformationally constrained ligands. J Med Chem 1993;36:1301-5.
10. 1A receptor. J Med Chem 1995;38:1295-308.
11. 1A receptor: Contribution of the molecular lipophilicity potential to three dimensional quantitative structure-affinity relationship models. J Med Chem 1996;39:126-34.
12. 1A receptor agonist. J Med Chem 1996;39:4439-50.
13. 1A Affinity/Selectivity. J Med Chem 1997;40:2653-6.
14. MOE. 2004. 03 (Molecular Operating Environment), Molecular Modeling System, Chemical Computing Group Inc: 1010 Sherbrooke Street West, Suite 91, Montreal, Quebec, Canada; p. H3A 2R7.
15. Campillo N, Goya P, Paez JA. Novel Arylpyrazino[2,3-c][1,2,6] thiadiazine 2,2-Dioxides as Platelet Aggregation Inhibitors. 2. Optimization by Quantitative Structure-Activity Relationships. J Med Chem 1999;42:3279-88.
16. Farr CD, Tabet MR, Ball Jr WJ. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J Med Chem 2002;45:3257-70.
17. Jaiswal M, Khadikar PV, Scozzafava A. Carbonic anhydrase inhibitors: The first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2004;14:3283-90.
18. 1-adrenergic receptor affinity by classical hansch analysis, artificial neural networks and computational simulation of ligand recognition. J Med Chem 2001;44:198-207.